Loading
Micrornas / Alzheimer Disease / Alzheimer's Disease · Journal article
Experimental Neurology · August 10, 2026
Encouraging direction, but not yet definitive.
In APP/PS1 transgenic mice and cultured neurons, intrahippocampal overexpression of let-7d-5p improved Morris water maze performance and reduced amyloid pathology by repressing bach1 expression. This is a mechanistic proof-of-concept study; translation to human AD therapy and clinical utility remain unestablished.
Transgenic animal model with adenoviral intervention and in vitro mechanistic studies. Eight-month-old male APP/PS1 transgenic mice and wild-type C57BL/6 J controls; SH-SY5Y human neuroblastoma cells treated with Aβ1-42. Intervention: Intrahippocampal injection of adenoviral let-7d-5p overexpression construct (Ad-let-7d-5p); let-7d-5p mimic transfection in cells. Compared with: Negative control adenovirus (Ad-NC) in mice; untransfected or mimic-negative control cells.
Let-7d-5p overexpression reduced escape latency and increased platform crossings in Morris water maze in AD model mice Let-7d-5p overexpression enhanced cell viability and inhibited apoptosis in Aβ1-42-treated SH-SY5Y cells Let-7d-5p directly targeted bach1 3'UTR and suppressed bach1 mRNA and protein expression in vitro and in vivo
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This preclinical work identifies let-7d-5p as a potential therapeutic target in AD through bach1 suppression. However, no human studies, dose-finding, or safety data are presented; further development and validation in clinical models would be needed before therapeutic translation.
A sound mechanistic study in transgenic mice and cell culture demonstrating let-7d-5p improves cognitive function via bach1 targeting, but lacking human evidence, powered comparison group, or a primary endpoint with effect size and confidence interval.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical work identifies let-7d-5p as a potential therapeutic target in AD through bach1 suppression. However, no human studies, dose-finding, or safety data are presented; further development and validation in clinical models would be needed before therapeutic translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. MicroRNAs (miRNAs) have emerged as critical modulators in Alzheimer's disease (AD) pathogenesis. The lethal-7 (let-7) family functions as key regulators of cell apoptosis, differentiation, and immune response. Herein, we explore the functions and underlying mechanisms of let-7d-5p in AD progression.Methods. Eight-month-old male APP/PS1 transgenic mice and wild-type C57BL/6 J mice were assigned to the model and control groups, respectively. Model mice received intrahippocampal injections of either a negative control adenovirus (Ad-NC) or a let-7d-5p overexpression adenovirus (Ad-let-7d-5p). The Morris water maze test was conducted to assess cognitive function. Hippocampal histopathological changes were evaluated using hematoxylin and eosin staining. Aβ deposition was detected via immunohistochemical staining. SH-SY5Y cells were transfected with let-7d-5p mimics prior to treatment with 10 μM Aβ1-42. Cell viability and apoptosis were examined using MTT assays and flow cytometry. The expression levels of let-7d-5p and bach1 were measured using RT-qPCR. Western blotting was conducted to evaluate bach1, Bcl-2, and cleaved caspase-3 protein levels. The binding relationship between let-7d-5p and bach1 was verified using luciferase reporter assays.Results. In vitro, Aβ1-42 treatment induced the downregulation of let-7d-5p and decrease of cell viability. However, overexpression of let-7d-5p significantly increased let-7d-5p level, enhanced cell viability and inhibited cell apoptosis of Aβ1-42-treated SH-SY5Y cells. Moreover, overexpression of let-7d-5p upregulated Bcl-2 protein levels and downregulated cleaved caspase-3 protein levels in Aβ1-42-treated SH-SY5Y cells. Furthermore, let-7d-5p overexpression ameliorated oxidative stress injury in Aβ1-42-treated SH-SY5Y cells. Importantly, bach1 upregulation counteracted the inhibitory effects of let-7d-5p overexpression on Aβ1-42-induced cellular injury. In vivo, let-7d-5p overexpression mitigated cognitive deficits of AD mice, as indicated by reduced escape latency and increased platform crossings. Additionally, let-7d-5p overexpression attenuated hippocampal histopathological changes and Aβ deposition in APP/PS1 mice. At the molecular level, let-7d-5p targeted bach1 3'UTR and repressed its mRNA and protein expression in vitro and in vivo. Rescue assays further validated that bach1 overexpression restored the protective effect of let-7d-5p on cognitive deficits and pathological injuries.Conclusion. Let-7d-5p alleviates cognitive deficits in AD by inhibiting Aβ deposition and neuronal apoptosis through targeting bach1.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.